New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 22, 2014
10:42 EDTNFLX, SRPT, YOKU Options with decreasing implied volatility: SRPT NFLX YOKU UVXY
News For SRPT;NFLX;YOKU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 >>
August 20, 2015
16:48 EDTNFLXOn The Fly: Top stock stories for Thursday
Subscribe for More Information
16:00 EDTNFLXOptions Update; August 20, 2015
iPath S&P 500 VIX Short-Term Futures up 1.49 to 17.70. Option volume leaders: AAPL BAC FB NFLX DIS INTC BABA MU
13:26 EDTNFLXOn The Fly: Top stock stories at midday
Subscribe for More Information
11:49 EDTSRPTOptions with increasing implied volatility
Options with increasing implied volatility: SRPT ACHN VIAV ZG RAD DIS ORCL SPY XLF OEX
11:22 EDTNFLXNetflix selling accelerates on heavier volume
Subscribe for More Information
11:16 EDTNFLXStocks with call strike movement; FB NFLX
Subscribe for More Information
10:19 EDTNFLXNetflix may test uptrend support
Subscribe for More Information
10:00 EDTYOKUOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:20 EDTYOKUOn The Fly: Pre-market Movers
Subscribe for More Information
09:17 EDTNFLXDisney hit with another downgrade on TV concerns
Subscribe for More Information
09:11 EDTYOKUYouku Tudou upgraded to Neutral following Q2 report at Mizuho
As previously reported, Mizuho upgraded Youku Tudou to Neutral from Underperform and maintained its $18 price target. The firm upgraded shares citing the Q2 beat and expects the consumer business to diversify and drive top line growth, and improve margin.
06:05 EDTYOKUYouku Tudou upgraded to Neutral from Underperform at Mizuho
August 19, 2015
18:05 EDTYOKUYouku Tudou sees Q3 revenue RMB 1.69B-RMB 1.78B
Subscribe for More Information
18:04 EDTYOKUYouku Tudou reports Q2 EPS (RMB 1.76) vs. (RMB 0.76) last year
Subscribe for More Information
16:00 EDTNFLXOptions Update; August 19, 2015
Subscribe for More Information
10:57 EDTNFLXT-Mobile promotion gives Netflix analyst greater confidence
UBS raised its price target on Netflix (NFLX) to $143 from $116, saying that its confidence in the company's outlook has improved following a promotion undertaken by T-Mobile (TMUS). WHAT'S NEW: T-Mobile recently began offering one free year of Netflix to consumers who switch to its wireless service, UBS analyst Doug Mitchelson wrote in a note to investors today. Mitchelson said that the promotion increases his confidence in the outlook for Netflix's U.S. business. Moreover, he believes that Netflix could "become a standard promotional tool" for wired and wireless broadband providers going forward. Although Netflix's stock "looks very expensive" in the near-term, the company's long-term opportunity is "extraordinary," given the potential size of the global streaming market, the analyst stated. Mitchelson's "upside case" for Netflix shares is $199 while his "downside case" is $55. The downside case assumes Hollywood starts restricting content licensing to streaming services like Netflix in attempt to slow their growth. He raised his price target on the name to $143 from $116 and kept a Buy rating on the shares. WHAT'S NOTABLE: On August 10, research firm Stifel raised its price target on Netflix to $143 from $128, saying that the company's U.S. subscriber base can reach 80M by 2024, above the midpoint of its guidance. PRICE ACTION: In mid-morning trading, Netflix fell 1% to $122.
09:33 EDTNFLXActive equity options trading on open
Active equity options trading on open: AAPL BAC FB BA TWTR NFLX WMT BABA
09:17 EDTSRPT'Female Viagra' approval seen as positive for Sarepta, BioMarin
The FDA's approval of the world's first drug designed to boost a woman's sexual desire is seen as boding well for companies awaiting critical decisions by the agency. FEMALE VIAGRA: The Food and Drug Administration yesterday approved flibanserin to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women. The drug, which will be sold under the name "Addyi" and is commonly referred to as the "female Viagra," is the first FDA-approved treatment for sexual desire disorders in men or women, the agency prominently stated in its press release. HSDD is characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance, the FDA explained. Addyi was approved with a risk evaluation and mitigation strategy as well as a Boxed Warning given the risk of severe hypotension and syncope in patients who drink alcohol during treatment. The drug is made by privately held Sprout Pharmaceuticals. ANALYST REACTION: Addyi's approval is "another sign of flexibility" by the FDA, especially for first-in-class therapies, Roth Capital analyst Debjit Chattopadhyay writes this morning in a note to investors. This bodes well for the approval of eteplirsen, drisapersen and Translarna, the analyst contends. Eteplirsen, designed by Sarepta Therapeutics (SRPT), and drisapersen, designed by BioMarin (BMRN), are experimental drugs being developed to treat Duchenne muscular dystrophy. Translarna, designed by PTC Therapeutics (PTCT), is already being sold in Europe as a treatment for DMD and is awaiting approval from the FDA. Duchenne muscular dystrophy is a form of muscular dystrophy affecting around 1 in 3,600 boys, which results in muscle degeneration and premature death. SAVING LIVES: While female sexual dysfunction is a clinical problem, eteplirsen is designed to save lives, Chattopadhyay points out. He has a Buy rating on Sarepta and noted his price target of $45 assumes accelerated approval for eteplirsen in the first quarter of 2016. Shares of the Massachusetts-based biopharmaceutical company closed yesterday at $35.69.
08:29 EDTSRPTFlibanserin approval bodes well for Sarepta, others, says Roth Capital
Subscribe for More Information
06:01 EDTNFLXNetflix price target raised to $143 from $116 at UBS
UBS analyst Doug Mitchelson raised his price target for Netflix (NFLX) shares to $143 after increasing his longer term revenue assumptions. The streaming service closed yesterday down $1.31 to $124.05. Mitchelson upped his 2020-2026 revenue estimates to reflect his belief that Netflix will successfully monetize its streaming platform beyond just monthly subscription fees, such as bundling and promoting third party services. He has increased confidence in the company's U.S. growth outlook after T-Mobile (TMUS) just launched a promotion for its wireless service that included one free year of Netflix. As competition among broadband providers intensifies, Netflix's inexpensive monthly streaming service could become one of the standard promotional tools, Mitchelson tells investors in a research note. The analyst's "upside case" for Netflix shares is $199 while his "downside case" is $55. The downside case assumes Hollywood starts restricting content licensing to streaming services like Netflix in attempt to slow their growth. Mitchelson keeps a Buy rating on Netflix.
1 | 2 | 3 | 4 | 5 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use